Detalhe da pesquisa
1.
HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia.
Int J Cancer
; 145(11): 3089-3100, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31044428
2.
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia.
Br J Cancer
; 121(2): 150-156, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31209327
3.
Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.
Br J Haematol
; 178(1): 81-93, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28419476
4.
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
Br J Haematol
; 185(1): 193-197, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29974955
5.
Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases.
Hematol Oncol
; 36(5): 801-803, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30110712
6.
Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
Clin Lymphoma Myeloma Leuk
; 19(10): 678-685.e4, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31371221
7.
Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases.
Oncotarget
; 8(66): 110727-110731, 2017 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29299182
8.
Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients.
Eur J Cancer
; 72: 103-111, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28027513